TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35701489

Group type: EXPERIMENTAL
Intervention: Resting-state functional connectivity
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Whole-brain connectivity at the voxel level
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Relationship between connectivity and network selectivity
Number of subjects: 19
Study: 35701541

Group type: EXPERIMENTAL
Intervention: RBD-based SARS-CoV-2 mRNA vaccine, specific dosage and duration not available
Number of subjects: 0
Study: 35701673

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2210
Study: 35702098

Group type: EXPERIMENTAL
Intervention: Salivary HBD-2 and LL-37 expression levels in T2DM patients with moderate to severe CP and poor blood sugar control
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Salivary HBD-2 and LL-37 levels
Number of subjects: 89
Study: 35702687

Group type: EXPERIMENTAL
Intervention: EpiSmart (epithelium-on)
Number of subjects: 101
Study: 35702830

Group type: EXPERIMENTAL
Intervention: DSM-5 POUD
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Pain-adjusted POUD
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Validators for POUD measures
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Pain-adjusted binary POUD
Number of subjects: 606
Study: 35703113

Group type: EXPERIMENTAL
Intervention: sasanlimab (immune checkpoint inhibitor) combined with stereotactic body radiation therapy (SBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: sasanlimab (immune checkpoint inhibitor)
Number of subjects: 0
Study: 35703267

Group type: EXPERIMENTAL
Intervention: Gadoquatrane (0.1 mmol Gd/kg body weight)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Gadoquatrane
Number of subjects: 1
Study: 35703367

Group type: COMPARATOR
Intervention: Multicomponent relaxation interventions (behavioral interventions)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Touch therapy
Number of subjects: 528

Group type: COMPARATOR
Intervention: Multicomponent relaxation intervention
Number of subjects: 528

Group type: COMPARATOR
Intervention: Bedtime story
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enhanced physical activity intervention
Number of subjects: 528

Group type: COMPARATOR
Intervention: Play
Number of subjects: 528
Study: 35703880

Group type: EXPERIMENTAL
Intervention: 11C-Metomidate PET-CT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Adrenal vein sampling (AVS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-surgical outcomes
Number of subjects: 25
Study: 35704034

Group type: EXPERIMENTAL
Intervention: Reproductive hormones (LH, FSH, inhibin B, AMH, E1, E2, SHBG) measured during minipuberty
Number of subjects: 98
Study: 35704372

Group type: EXPERIMENTAL
Intervention: Combined iTBS+yoga intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: iTBS+yoga intervention
Number of subjects: 20
Study: 35704376

Group type: EXPERIMENTAL
Intervention: PLUSS model (integrative working model with multiprofessional competence and intersectoral collaboration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PLUSS model
Number of subjects: 0
Study: 35704787

Group type: EXPERIMENTAL
Intervention: Venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA
Number of subjects: 60
Study: 35704795

Group type: EXPERIMENTAL
Intervention: T-cell-dependent vaccine against Haemophilus influenzae type b (Hib)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: T-cell-independent pneumococcal polysaccharide vaccine (PPSV)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hib vaccination responders
Number of subjects: 56
Study: 35704976

Group type: COMPARATOR
Intervention: Fully vaccinated
Number of subjects: 2090
Study: 35705312

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 106
Study: 35705345

Group type: EXPERIMENTAL
Intervention: Orthodontic interventions (maxillary expansion, mandibular advancement, or maxillary complex advancement with skeletal anchored headgear)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (orthodontic intervention declined)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Orthodontic interventions
Number of subjects: 70
Study: 35705362

Group type: EXPERIMENTAL
Intervention: Highest income quintile (≥€54,000)
Number of subjects: 203154

Group type: COMPARATOR
Intervention: Lowest income quintile (≤€12,000)
Number of subjects: 203154
Study: 35705788

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg
Number of subjects: 593
Study: 35705844

Group type: EXPERIMENTAL
Intervention: Years living in the US
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: English speaking proficiency
Number of subjects: 328
Study: 35706068

Group type: EXPERIMENTAL
Intervention: Entre Nosotras + stress management intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Entre Nosotras alone
Number of subjects: 220
Study: 35706358

Group type: EXPERIMENTAL
Intervention: Model averaging algorithm
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Maximum a posteriori prediction
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Model averaging using four models
Number of subjects: 54

Group type: COMPARATOR
Intervention: Single-model approach
Number of subjects: 54
Study: 35706483

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) machine learning model
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Logistic regression prediction model
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: RF model validated with additional 117 patients
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Logistic regression model validated with additional 117 patients
Number of subjects: 1117
Study: 35706792

Group type: EXPERIMENTAL
Intervention: Postoperative VTE prevention measures
Number of subjects: 1217
Study: 35707634

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (drinkers)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: Persistent drinkers
Number of subjects: 907

Group type: COMPARATOR
Intervention: Non-drinkers
Number of subjects: 907
Study: 35707705

Group type: EXPERIMENTAL
Intervention: Single-channel EEG features (A0)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Single-channel EEG features (ST4)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EEG features (Theta, Delta, A0, VC9)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EEG feature (VC9)
Number of subjects: 82
Study: 35707743

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with parents of children with cancer
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Presence of positive attitudes toward the children's cancer
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low level of confidence
Number of subjects: 23
Study: 35707873

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg SC Q4W
Number of subjects: 65
Study: 35708131

Group type: EXPERIMENTAL
Intervention: Camp Kidpower intervention (CC training)
Number of subjects: 44
Study: 35708166

Group type: EXPERIMENTAL
Intervention: VR-assisted cognitive behavioural therapy for psychosis (CBTp)
Number of subjects: 16
Study: 35708466

Group type: EXPERIMENTAL
Intervention: Flunarizine treatment for 3 months
Number of subjects: 72
Study: 35708634

Group type: EXPERIMENTAL
Intervention: Alcohol Drinks
Number of subjects: 0
Study: 35708744

Group type: EXPERIMENTAL
Intervention: Use of smartphone health apps
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Health apps related to wellness, prevention, and fitness
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Health apps related to medication, treatments, and follow-up care
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Factors associated with health app use
Number of subjects: 739
Study: 35708763

Group type: EXPERIMENTAL
Intervention: Distribution of self-diagnosis and self-treatment kits after training by health mediators (facilitators).
Number of subjects: 4863

Group type: EXPERIMENTAL
Intervention: Mobile data collection using Android tablets with ODK Collect.
Number of subjects: 4863

Group type: EXPERIMENTAL
Intervention: Custom R package and dashboard web app for data management.
Number of subjects: 4863
Study: 35708794

Group type: EXPERIMENTAL
Intervention: DPEG
Number of subjects: 47

Group type: COMPARATOR
Intervention: IRG
Number of subjects: 47
Study: 35709178

Group type: EXPERIMENTAL
Intervention: Cannabis Cessation Program (CCP), 8-week program
Number of subjects: 102
Study: 35709957

Group type: EXPERIMENTAL
Intervention: Cognitive and adaptive behavior functions analysis
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Development quotients for cognition and adaptive behavior
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Volumetric MRI analysis of brain
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Heparan sulfate (HS) and heparan sulfate nonreducing ends (HS-NRE) levels measurement
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Signs of hepatomegaly
Number of subjects: 65
Study: 35710225

Group type: EXPERIMENTAL
Intervention: Active Video Game activities
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sedentary behavior (watching television)
Number of subjects: 32
Study: 35710250

Group type: EXPERIMENTAL
Intervention: Xpert-Ultra
Number of subjects: 1009
Study: 35710265

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35710326

Group type: EXPERIMENTAL
Intervention: Lung ultrasound performed before surgery to evaluate residual pulmonary alterations (≥ 3 B-lines and pleural thickening)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pulmonary compliance determination during surgery
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Postoperative pulmonary complications collected during hospital stay
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Incidence of postoperative pulmonary complications
Number of subjects: 103
Study: 35710334

Group type: EXPERIMENTAL
Intervention: Oscillometry
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 80
Study: 35710347

Group type: EXPERIMENTAL
Intervention: Active in My Home (AiMH) intervention, consisting of five individual and three group sessions led by an occupational therapist.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active in My Home (AiMH) intervention.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active in My Home (AiMH) intervention satisfaction rated by participants and staff at T2.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active in My Home (AiMH) intervention satisfaction.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active in My Home (AiMH) intervention satisfaction rated by staff and participants at T2.
Number of subjects: 29
Study: 35710368

Group type: EXPERIMENTAL
Intervention: Baseline to FU1 (March-June 2020)
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: Baseline to FU2 (June-September 2020)
Number of subjects: 1877
Study: 35710369

Group type: EXPERIMENTAL
Intervention: T2D
Number of subjects: 0

Group type: COMPARATOR
Intervention: EU
Number of subjects: 0

Group type: COMPARATOR
Intervention: IR
Number of subjects: 0
Study: 35710520

Group type: EXPERIMENTAL
Intervention: Remote Video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote Video plus Coaching
Number of subjects: 0
Study: 35710578

Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 202

Group type: COMPARATOR
Intervention: 4F-PCC
Number of subjects: 202
Study: 35710733

Group type: EXPERIMENTAL
Intervention: Total metabolic tumor volume (TMTV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor dissemination (Dmax)
Number of subjects: 0
Study: 35710741

Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin in combination with nivolumab
Number of subjects: 84
Study: 35710944

Group type: EXPERIMENTAL
Intervention: International Weight Control Registry (IWCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection methods including questionnaires and objective measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative information from participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental data from public sources
Number of subjects: 0
Study: 35711259

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) therapy
Number of subjects: 652
Study: 35711298

Group type: EXPERIMENTAL
Intervention: Memory-reframing intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (normal reminiscing)
Number of subjects: 17
Study: 35711355

Group type: EXPERIMENTAL
Intervention: 3D printed mitral valve models
Number of subjects: 6
Study: 35711382

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2070
Study: 35711561

Group type: EXPERIMENTAL
Intervention: Amino acid-based formula
Number of subjects: 190

Group type: COMPARATOR
Intervention: Extensively hydrolyzed formula
Number of subjects: 190
Study: 35712095

Group type: EXPERIMENTAL
Intervention: Late-onset LN group
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Early-onset LN group
Number of subjects: 1264
Study: 35712110

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham laser acupuncture (SLA)
Number of subjects: 3
Study: 35712111

Group type: EXPERIMENTAL
Intervention: PMA-zeolite supplementation (long-term, 4 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMA-zeolite supplementation (short-term, 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMA-zeolite supplementation (medium-term, 12 weeks)
Number of subjects: 0
Study: 35712433

Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 24
Study: 35712448

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) training using Axon EEG NFB systems, 32-48 sessions over 8 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) training
Number of subjects: 16
Study: 35712486

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg) and Anlotinib (12 mg once daily on days 1 to 14 every 3 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sintilimab plus Anlotinib
Number of subjects: 20
Study: 35712797

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir (100 mg nirmatrelvir with 100 mg ritonavir)
Number of subjects: 34
Study: 35712977

Group type: EXPERIMENTAL
Intervention: Permanent implantable collagen tile brachytherapy for brain tumors
Number of subjects: 0
Study: 35713008

Group type: EXPERIMENTAL
Intervention: Circulating IL-6 levels
Number of subjects: 4334
Study: 35713054

Group type: EXPERIMENTAL
Intervention: Diet-related mobile application based on artificial intelligence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care group with pamphlet instructions
Number of subjects: 0
Study: 35713149

Group type: EXPERIMENTAL
Intervention: Working from home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35713209

Group type: EXPERIMENTAL
Intervention: Weekly Calendar Planning Activity (WCPA)
Number of subjects: 0
Study: 35713300

Group type: COMPARATOR
Intervention: Tixagevimab/cilgavimab
Number of subjects: 9749

Group type: COMPARATOR
Intervention: Casirivimab/imdevimab
Number of subjects: 9749

Group type: COMPARATOR
Intervention: Bamlanivimab
Number of subjects: 9749
Study: 35713509

Group type: EXPERIMENTAL
Intervention: Early oral β-blocker therapy (users)
Number of subjects: 43640

Group type: EXPERIMENTAL
Intervention: High-dose β-blocker therapy (metoprolol-equivalent dose ≥50 mg/day)
Number of subjects: 43640

Group type: EXPERIMENTAL
Intervention: Low-dose β-blocker therapy (metoprolol-equivalent dose <50 mg/day)
Number of subjects: 43640

Group type: COMPARATOR
Intervention: Metoprolol vs. Bisoprolol
Number of subjects: 43640
Study: 35713539

Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown
Number of subjects: 0
Study: 35713551

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0
Study: 35713599

Group type: EXPERIMENTAL
Intervention: Higher frequency of mantram repetition practice
Number of subjects: 0
Study: 35713720

Group type: EXPERIMENTAL
Intervention: Asynchronous TeleHealth care (web-based questionnaire)
Number of subjects: 33

Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 33
Study: 35713873

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 372
Study: 35713929

Group type: EXPERIMENTAL
Intervention: sRAGE treatment
Number of subjects: 0
Study: 35713944

Group type: EXPERIMENTAL
Intervention: forDiabetes mobile app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 35714051

Group type: EXPERIMENTAL
Intervention: Higher number of stressful life events (2010-11)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Not applicable (control group with optimal LDL cholesterol and triglyceride levels)
Number of subjects: 224
Study: 35714099

Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP) for MSK pain
Number of subjects: 7785
Study: 35714311

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) - 17 ledipasvir/sofosbuvir, 8 sofosbuvir plus ribavirin, 15 sofosbuvir/velpatasvir
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 40
Study: 35714349

Group type: EXPERIMENTAL
Intervention: Insulin Replacement
Number of subjects: 0
Study: 35714426

Group type: EXPERIMENTAL
Intervention: Blended learning mentoring education containing a cultural competence component (Intervention group)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Online mentoring education lacking a cultural competence component (Control group)
Number of subjects: 111
Study: 35714431

Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT) for 12-24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT) for 6-12 months
Number of subjects: 0
Study: 35714445

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 22120
Study: 35714649

Group type: EXPERIMENTAL
Intervention: Comprehensive diagnostic procedures for encephalitis
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Japanese encephalitis virus
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Dengue virus
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Influenza virus
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Herpes simplex virus 1
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Mycobacterium tuberculosis
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Enterovirus A71
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Other pathogens
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Autoimmune encephalitis
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Severe neurological sequelae
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Risk factors for unfavourable outcomes
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year after inclusion
Number of subjects: 664
Study: 35714666

Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound focal therapy
Number of subjects: 101
Study: 35714735

Group type: EXPERIMENTAL
Intervention: AAV2-hCHM subretinal injections
Number of subjects: 15
Study: 35715176

Group type: EXPERIMENTAL
Intervention: Public and Patient Engagement Evaluation Tool (PPEET) questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 0
Study: 35715340

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a median dose of 36.25 Gy in five fractions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 24
Study: 35715405

Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab with chemotherapy
Number of subjects: 0
Study: 35715492

Group type: EXPERIMENTAL
Intervention: Cortisol awakening response in EPT children
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cortisol awakening response in term-born children
Number of subjects: 139
Study: 35715566

Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec
Number of subjects: 14
Study: 35715567

Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec
Number of subjects: 15
Study: 35715627

Group type: EXPERIMENTAL
Intervention: Cobimetinib (tablet) at a recommended Phase II dose (RP2D) of 0.8 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cobimetinib (suspension) at a recommended Phase II dose (RP2D) of 1.0 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cobimetinib (tablet and suspension)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cobimetinib
Number of subjects: 56
Study: 35715631

Group type: EXPERIMENTAL
Intervention: Physical activity classification (≦0.33 MET-h/wk, 0.34-16.65 MET-h/wk, ≥16.6 MET-h/wk)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Physical activity dose classification
Number of subjects: 1075
Study: 35715801

Group type: EXPERIMENTAL
Intervention: Seraph® 100 Microbind® Affinity Blood Filter treatment
Number of subjects: 15
Study: 35715823

Group type: EXPERIMENTAL
Intervention: Model trained on stroke data
Number of subjects: 20

Group type: COMPARATOR
Intervention: Model trained on control data
Number of subjects: 20
Study: 35715980

Group type: EXPERIMENTAL
Intervention: Maternal egg intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline and L/Z intake interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline, L/Z, and DHA interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L/Z intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline and L/Z interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L/Z and DHA interaction
Number of subjects: 0
Study: 35716238

Group type: EXPERIMENTAL
Intervention: Pediatric Diabetes Routines Questionnaire for Parents of Young Children (PDRQ-PYC)
Number of subjects: 173
Study: 35716331

Group type: EXPERIMENTAL
Intervention: High broad-spectrum sunscreen medical device (MD) containing UVB and UVA filters and 1% ectoin, applied at a dosage of 2 mg/cm².
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated control side (no sunscreen applied).
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High broad-spectrum sunscreen medical device (MD).
Number of subjects: 13